Update on the Management of Hepatitis C in Liver Transplant Recipients.
Hepatic failure due to hepatitis C is the leading indicator for orthotopic liver transplantation (OLT) in the United States. Unfortunately, recurrent hepatitis C virus infection is essentially universal following orthotopic liver transplantation. Although significant advances have been made in the past decade for the treatment of hepatitis C, a similar level of success has not yet been achieved for most hepatitis C virus-infected liver transplant recipients. In addition, deleterious side effects of the currently available antiviral agents continue to significantly hamper their use. Several recent reports, however, indicate that newer immunosuppressive regimens combined with novel modifications of existing treatment paradigms will likely lead to improved clinical outcomes for the hepatitis C virus-infected liver transplant recipient.
A Bobak
David
D
Division of Infectious Diseases, University Hospitals of Cleveland/CWRU School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106, USA. dab39@po.cwru.edu
Yadavalli
Gopal
G